PROSION Therapeutics utilizes a proprietary platform that combines small molecules and biologics to create ProM-based inhibitors targeting proline-rich motif binding domains, which are associated with undruggable disease drivers in oncology and other pathologies. This technology aims to provide therapeutic options for diseases such as cancer, diabetes, and neurodegenerative disorders, addressing significant unmet medical needs and improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease drivers, particularly in oncology, are considered "undruggable" due to their reliance on proline-rich motif (ProM) binding domains, which are difficult to target with conventional therapies. This limitation leaves significant unmet medical needs across various pathologies.
Solution
PROSION Therapeutics utilizes a platform that combines small molecules and biologics to create ProM-based inhibitors. These inhibitors target proline-rich motif binding domains, effectively unlocking previously undruggable disease drivers. By mimicking the Polyproline-II-Helix, PROSION's technology enables the development of highly selective small molecule inhibitors. This approach offers a new therapeutic modality to address critical orchestrator proteins involved in urgent diseases, initially focusing on oncology and expanding to other therapeutic areas.
Target Audience
The primary target audience includes patients and healthcare providers seeking novel therapeutic options for diseases with high unmet needs, particularly in oncology and related pathologies.
Features
- Proprietary ProM-based inhibitors that mimic the Polyproline-II-Helix structure.
- Small molecule inhibitors designed for high selectivity against previously undruggable protein targets.
- Pipeline focused on oncology, targeting fundamental drivers of tumor progression and metastasis.
- Expansion into therapeutic applications beyond oncology, including cardiovascular, infectious, and neurodegenerative diseases.